Background Granisetron is a first-generation 5-HT3-receptor antagonist that has shown efficacy in preventing postoperative nausea and vomiting (PONV). In this randomized double-blind parallel-group clinical trial, we assessed the efficacy of generic granisetron versus Kytril®, in the prevention of PONV in patients undergoing general anesthesia for gynaecological surgeries. Method One hundred an...

background granisetron is a first-generation 5-ht3-receptor antagonist that has shown efficacy in preventing postoperative nausea and vomiting (ponv). in this randomized double-blind parallel-group clinical trial, we assessed the efficacy of generic granisetron versus kytril®, in the prevention of ponv in patients undergoing general anesthesia for gynaecological surgeries. method one hundred an...

Background Granisetron is a first-generation 5-HT3-receptor antagonist that has shown efficacy in preventing postoperative nausea and vomiting (PONV). In this randomized double-blind parallel-group clinical trial, we assessed the efficacy of generic granisetron versus Kytril®, in the prevention of PONV in patients undergoing general anesthesia for gynaecological surgeries. Method One hundred an...

Background Granisetron is a first-generation 5-HT3-receptor antagonist that has shown efficacy in preventing postoperative nausea and vomiting (PONV). In this randomized double-blind parallel-group clinical trial, we assessed the efficacy of generic granisetron versus Kytril®, in the prevention of PONV in patients undergoing general anesthesia for gynaecological surgeries. Method One hundred an...

In this randomized, double-blind, parallel group, placebo-controlled, dose-ranging study, we have compared three doses (0.1 mg, 1.0 mg and 3.0 mg) of the 5-HT3 receptor antagonist, granisetron (Kytril), as prophylactic therapy for the prevention of postoperative nausea and vomiting. The aims were to determine the optimal dose of granisetron and to evaluate its safety profile. We studied 527 adu...

1. Del Giglio A, Soares HP, Caparroz C et al. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomit. Results of a meta-analysis of randomised controlled trials. Cancer 2000; 89: 2301–2308. 2. Grunberg SM. Phase I and other dose-ranging studies of granisetron. Semin Oncol 1992; 19 (Suppl 10): 16–22. 3. Perez EA, Hesketh P, Sandbach J et al. Comparison ...

Since the 1990s, new antiemetic agents have significantly reduced the incidence of nausea and vomiting associated with chemotherapy. Specifically, these agents are the serotonin receptor antagonists and consist of dolasetron (Anzamet, Aventis Pharmaceuticals, Bridgewater, NJ), granisetron (Kytril, Roche Pharmaceuticals, Nutley, NJ), ondansetron (Zofran, GlaxoSmithKline, Research Triangle Park, ...